ACTIVE

LINDEPHAR

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

55,6 k €

+138.2% YoY

Gross margin

592,1 k €

+9.8% YoY

Equity

791,2 k €

+7.6% YoY

Workforce

5,6 ETP

-8.2% YoY

What does LINDEPHAR do?

LINDEPHAR is a Public limited company incorporated in 1991. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Evergem. It employs on average 5,6 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0445.084.795

Incorporation

09/09/1991

Legal form

Public limited company

Registered office

Lindenlaan 26
9940 Evergem · FlandreSee on map

Contributed capital

62 000,00 €

Latest accounts

31/12/2025

Average workforce

5,6 ETP

Activities (NACE)

47730Dispensing chemist in specialised stores· main 47730Dispensing chemist in specialised stores 52310Warehousing and support activities for transportation

Joint committees (1)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 20 financial years

	2025		2024		2023		2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011		2010		2009		2008		2007		2006
Income statement
Gross margin	592,1 k €	+9.8%	539,4 k €	+11.6%	483,3 k €	-5.7%	512,6 k €	-10.4%	572 k €	-9.8%	633,9 k €	+27.4%	497,7 k €	+33.2%	373,7 k €	-13.6%	432,4 k €	+53.4%	281,9 k €	+10.4%	255,4 k €	+7.8%	236,9 k €	-14.6%	277,2 k €	+77.0%	156,7 k €	+18.9%	131,7 k €	+52.7%	86,2 k €	-52.8%	182,6 k €	-25.4%	244,9 k €	+1.9%	240,4 k €	+8.7%	221,2 k €
EBITDA	188,8 k €	+27.1%	148,5 k €	+35.9%	109,3 k €	-40.4%	183,4 k €	-42.5%	318,8 k €	-20.3%	399,9 k €	+25.2%	319,4 k €	+67.6%	190,6 k €	-26.3%	258,7 k €	+225%	79,6 k €	+68.0%	47,4 k €	-31.0%	68,6 k €	-25.6%	92,2 k €	+1280%	6,7 k €	-50.6%	13,5 k €	+139%	-34,9 k €	-140%	86,6 k €	-49.7%	172 k €	-0.6%	173 k €	+11.7%	154,9 k €
Operating result	99,8 k €	+68.4%	59,3 k €	+169%	22 k €	-77.1%	95,9 k €	-62.5%	255,5 k €	-25.9%	344,7 k €	+31.7%	261,7 k €	+96.6%	133,1 k €	-31.7%	194,9 k €	+837%	20,8 k €	+322%	-9,4 k €	-178%	12 k €	-65.2%	34,6 k €	+220%	-28,9 k €	-51.6%	-19,1 k €	+53.1%	-40,6 k €	-150%	80,7 k €	-46.9%	152,1 k €	-0.6%	153 k €	+13.0%	135,4 k €
Net result	55,6 k €	+138%	23,3 k €	+349%	-9,4 k €	-117%	55,4 k €	-72.4%	200,9 k €	-28.1%	279,6 k €	+37.0%	204 k €	+92.4%	106 k €	-33.7%	159,9 k €	+3989%	-4,1 k €	+90.0%	-40,9 k €	-174%	-14,9 k €	-169%	21,7 k €	+159%	-36,5 k €	-47.5%	-24,7 k €	+8.5%	-27,1 k €	-144%	61,8 k €	-40.3%	103,5 k €	+1.3%	102,1 k €	-24.3%	134,8 k €
Balance sheet
Equity	791,2 k €	+7.6%	735,6 k €	+3.3%	712,3 k €	-1.3%	721,6 k €	+8.3%	666,3 k €	+43.2%	465,4 k €	+38.6%	335,8 k €	+19.2%	281,8 k €	+2.2%	275,8 k €	+77.0%	155,8 k €	-2.6%	159,9 k €	-20.4%	200,9 k €	-6.9%	215,8 k €	+11.2%	194,2 k €	-15.8%	230,7 k €	-9.7%	255,4 k €	-9.6%	282,5 k €	-23.8%	370,7 k €	+38.7%	267,2 k €	+61.9%	165,1 k €
Total assets	1,6 M €	-15.6%	1,9 M €	-2.6%	2 M €	-3.0%	2 M €	+17.4%	1,7 M €	+18.4%	1,5 M €	-2.5%	1,5 M €	-30.8%	2,2 M €	+53.9%	1,4 M €	+6.4%	1,3 M €	+3.6%	1,3 M €	+5.9%	1,2 M €	+5.7%	1,1 M €	+22.7%	936,9 k €	+5.5%	887,8 k €	+70.1%	522 k €	-13.9%	606,2 k €	+21.2%	500 k €	+30.6%	382,9 k €	-7.0%	411,7 k €
Cash	73,7 k €	+72.8%	42,7 k €	-61.7%	111,4 k €	-7.4%	120,4 k €	+63.6%	73,6 k €	-44.9%	133,5 k €	+84.8%	72,2 k €	+50.3%	48,1 k €	-34.8%	73,7 k €	+47.9%	49,8 k €	+123%	22,4 k €	-73.8%	85,5 k €	+66.3%	51,4 k €	+6.4%	48,3 k €	-6.8%	51,8 k €	-58.0%	123,5 k €	-58.8%	299,9 k €	+61.1%	186,1 k €	+154%	73,4 k €	-17.9%	89,4 k €
Debts	839,6 k €	-29.8%	1,2 M €	-5.8%	1,3 M €	-4.1%	1,3 M €	+22.9%	1,1 M €	+7.0%	1 M €	-14.3%	1,2 M €	-38.2%	1,9 M €	+66.4%	1,1 M €	-3.0%	1,2 M €	+4.5%	1,1 M €	+11.1%	1 M €	+8.5%	934,1 k €	+25.8%	742,8 k €	+13.0%	657,1 k €	+146%	266,6 k €	-17.5%	323,3 k €	+150%	129,3 k €	+11.8%	115,7 k €	-53.1%	246,6 k €
Other
Workforce	5,6 ETP	-8.2%	6,1 ETP	-10.3%	6,8 ETP	+13.3%	6,0 ETP	+46.3%	4,1 ETP	-2.4%	4,2 ETP	+10.5%	3,8 ETP	+8.6%	3,5 ETP	-10.3%	3,9 ETP	-11.4%	4,4 ETP	+2.3%	4,3 ETP	+7.5%	4,0 ETP	+8.1%	3,7 ETP	+5.7%	3,5 ETP	+59.1%	2,2 ETP	+10.0%	2,0 ETP	+17.6%	1,7 ETP	+30.8%	1,3 ETP	0.0%	1,3 ETP	-7.1%	1,4 ETP

Estimate

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 1 active · 19 ended

Active mandates

DECURA PHARMA

Director · since 09 juin 2022 · 0817.127.010

Represented by Ann Raes

Active

Ended mandates

DECURA PHARMA

Director · since 09 juin 2022 · 0817.127.010

Represented by Ann Raes

Ended

Decan Comm.V

Director · since 20 mai 2015 · until 20 mai 2021 · 0878.303.821

Represented by Andy Decuypere

Ended

Decan

Director · since 27 juillet 2009 · until 26 juillet 2015 · 0878.303.821

Represented by Andy Decuypere

Ended

DECURA PHARMA

Managing director · since 27 juillet 2009 · until 26 juillet 2015 · 0817.127.010

Represented by Ann Raes

Ended

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	24/07/2026	18/07/2025	17/07/2024	06/07/2023	20/06/2022	29/07/2021
General meeting	30/06/2026	20/06/2025	20/06/2024	20/06/2023	21/05/2022	29/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

20 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	30/06/2026	24/07/2026	Dutch	PDF
Abridged model	31/12/2024	20/06/2025	18/07/2025	Dutch	PDF
Abridged model	31/12/2023	20/06/2024	17/07/2024	Dutch	PDF
Abridged model	31/12/2022	20/06/2023	06/07/2023	Dutch	PDF
Abridged model	31/12/2021	21/05/2022	20/06/2022	Dutch	PDF
Abridged model	31/12/2020	29/06/2021	29/07/2021	Dutch	PDF
Abridged model	31/12/2019	31/08/2020	30/09/2020	Dutch	PDF
Abridged model	31/12/2018	18/05/2019	25/09/2019	Dutch	PDF
Abridged model	31/12/2017	30/06/2018	30/07/2018	Dutch	PDF
Abridged model	31/12/2016	30/06/2017	31/08/2017	Dutch	PDF
Abridged model	31/12/2015	30/06/2016	31/08/2016	Dutch	PDF
Abridged model	31/12/2014	06/06/2015	06/07/2015	Dutch	PDF
Abridged model	31/12/2013	30/06/2014	28/07/2014	Dutch	PDF
Abridged model	31/12/2012	30/06/2013	26/07/2013	Dutch	PDF
Abridged model	31/12/2011	30/06/2012	19/07/2012	Dutch	PDF
Abridged model	31/12/2010	30/06/2011	30/09/2011	Dutch	PDF
Abridged model	31/12/2009	20/06/2010	19/07/2010	Dutch	PDF
Abridged model	31/12/2008	05/06/2009	15/09/2009	Dutch	PDF
Abridged model	31/12/2007	17/05/2008	26/08/2008	Dutch	PDF
Abridged model	31/12/2006	19/05/2007	30/07/2007	Dutch	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 1 active · 19 ended

Active mandates

DECURA PHARMA

Director · since 09 juin 2022 · 0817.127.010

Represented by Ann Raes

Active

Ended mandates

DECURA PHARMA

Director · since 09 juin 2022 · 0817.127.010

Represented by Ann Raes

Ended

Decan Comm.V

Director · since 20 mai 2015 · until 20 mai 2021 · 0878.303.821

Represented by Andy Decuypere

Ended

Decan

Director · since 27 juillet 2009 · until 26 juillet 2015 · 0878.303.821

Represented by Andy Decuypere

Ended

DECURA PHARMA

Managing director · since 27 juillet 2009 · until 26 juillet 2015 · 0817.127.010

Represented by Ann Raes

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates23/06/2022
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - DOEL - ONTSLAGEN - BENOEMINGEN - ALGEMENE VERGADERING
PDF
Mandates28/09/2021
ONTSLAGEN - BENOEMINGEN
PDF
Mandates23/11/2015
ONTSLAGEN - BENOEMINGEN
PDF
Registered office27/03/2013
MAATSCHAPPELIJKE ZETEL
PDF
Mandates07/08/2009
ONTSLAGEN - BENOEMINGEN
PDF
Mandates01/08/2007
ONTSLAGEN - BENOEMINGEN
PDF
Mandates02/05/2006
ONTSLAGEN - BENOEMINGEN
PDF
Other11/08/2004
DIVERSEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 202555,6 k €↑
2024
Annual accounts 202423,3 k €↑
2023
Annual accounts 2023-9,4 k €↓
2022
Annual accounts 202255,4 k €↓
2021
Annual accounts 2021200,9 k €↓
2020
Annual accounts 2020279,6 k €↑
2019
Annual accounts 2019204 k €↑
2018
Annual accounts 2018106 k €↓
2017
Annual accounts 2017159,9 k €↑
2016
Annual accounts 2016-4,1 k €↑
2015
Annual accounts 2015-40,9 k €↓
2014
Annual accounts 2014-14,9 k €↓
2013
Annual accounts 201321,7 k €↑
2012
Annual accounts 2012-36,5 k €↓
2011
Annual accounts 2011-24,7 k €↑
2010
Annual accounts 2010-27,1 k €↓
2009
Annual accounts 200961,8 k €↓
2008
Annual accounts 2008103,5 k €↑
2007
Annual accounts 2007102,1 k €↓
2006
Annual accounts 2006134,8 k €
09/09/1991
IncorporationPublic limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

LINDEPHAR

Overview

What does LINDEPHAR do?

Trend over 20 financial years

Indicative valuation

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline